| ICOS Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutic products. It markets Cialis (tadalafil) for the treatment of erectile dysfunction through Lilly ICOS LLC, its joint venture with Eli Lilly and Company, in North America and Europe. North America includes the United States, Canada, and Mexico. Europe includes Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom plus Finland, Iceland, and Norway. In addition, the companys IC485 is an orally administered, small molecule inhibitor of the type 4 cyclic adenosine monophosphate phosphodiesterase enzyme. As of March 31, 2004, IC485 was in a Phase 2 clinical study for the potential treatment of chronic obstructive pulmonary disease. The company was incorporated in 1989 and is headquartered in Bothell, Washington. |
